<DOC>
	<DOCNO>NCT01637259</DOCNO>
	<brief_summary>Chronic kidney disease ( CKD ) emerge problem patient treat HIV . Antiretroviral therapy associate renal dysfunction predominantly describe term reduce glomerular filtration ( eGFR ) . Proteinuria key component CKD may occur absence significant reduction eGFR . This substudy exploration change urinary protein excretion randomise , open-label study evaluate efficacy safety MVC switch either nucleoside nucleotide analogue reverse transcriptase inhibitor ( N ( ) RTI ) boost protease inhibitor ( PI/r ) HIV-1 infected individual stable , well-controlled plasma HIV-RNA take first N ( ) RTI + PI/r regimen combination antiretroviral therapy ( cART ) .</brief_summary>
	<brief_title>MARCH Renal Substudy</brief_title>
	<detailed_description>The aim substudy MARCH characterize change protein salt excretion kidney utilise randomise arm parent study MARCH . The investigator hypothesize improvement proteinuria switch maraviroc contain regimen .</detailed_description>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Provision write , informed consent participation substudy Enrolled substudy either week 0 visit main study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>proteinuria</keyword>
	<keyword>HIV</keyword>
</DOC>